BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DR10624 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DR10624\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07050134-228@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:DR10624: Phase na readout est. (NCT07050134)
DESCRIPTION:DR10624\, phase na.\nStudy: A Trial to Evaluate the Efficacy an
 d Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Athe
 rosclerotic Plaque\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dr10624#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07050134
URL:https://assetmemo.bio/drug/dr10624#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07848880-228@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:DR10624: Phase 2 readout est. (NCT07848880)
DESCRIPTION:DR10624\, phase 2.\nStudy: A Phase 2 Study to Evaluate the Effi
 cacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia 
 and Diabetic Kidney Disease\nEstimated primary completion: April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dr10624#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07848880
URL:https://assetmemo.bio/drug/dr10624#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693777-228@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:DR10624: Phase 3 readout est. (NCT07693777)
DESCRIPTION:DR10624\, phase 3\, Severe Hypertriglyceridemia.\nStudy: A Phas
 e III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects 
 With Severe Hypertriglyceridemia\nEstimated primary completion: 14 Februar
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dr10624#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07693777
URL:https://assetmemo.bio/drug/dr10624#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680829-228@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:DR10624: Phase 3 readout est. (NCT07680829)
DESCRIPTION:DR10624\, phase 3\, Severe Hypertriglyceridemia.\nStudy: A Phas
 e 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglycer
 idemia\nEstimated primary completion: June 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/dr10624#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07680829
URL:https://assetmemo.bio/drug/dr10624#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
